ProShare Advisors’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$137K Sell
30,551
-5,610
-16% -$24.5K ﹤0.01% 1664
2025
Q4
$174K Buy
36,161
+3,446
+11% +$15.5K ﹤0.01% 1763
2025
Q3
$149K Sell
32,715
-5,480
-14% -$20.1K ﹤0.01% 1772
2025
Q2
$118K Sell
38,195
-1,977
-5% -$6.57K ﹤0.01% 1848
2025
Q1
$140K Sell
40,172
-9,949
-20% -$33.2K ﹤0.01% 1773
2024
Q4
$164K Buy
50,121
+11,359
+29% +$41.8K ﹤0.01% 1946
2024
Q3
$149K Buy
38,762
+10,144
+35% +$38.9K ﹤0.01% 1804
2024
Q2
$88.4K Sell
28,618
-5,897
-17% -$17.7K ﹤0.01% 1681
2024
Q1
$89K Buy
34,515
+2,829
+9% +$7.33K ﹤0.01% 1840
2023
Q4
$79.2K Buy
31,686
+4,516
+17% +$8.84K ﹤0.01% 1811
2023
Q3
$55.2K Buy
27,170
+188
+0.7% +$394 ﹤0.01% 1709
2023
Q2
$62.1K Buy
26,982
+2,763
+11% +$7.19K ﹤0.01% 1752
2023
Q1
$73.4K Sell
24,219
-3,339
-12% -$9.42K ﹤0.01% 1637
2022
Q4
$64.2K Buy
27,558
+3,043
+12% +$7.28K ﹤0.01% 1711
2022
Q3
$47K Buy
24,515
+802
+3% +$1.89K ﹤0.01% 1666
2022
Q2
$64K Sell
23,713
-7,367
-24% -$18.9K ﹤0.01% 1670
2022
Q1
$93K Sell
31,080
-5,519
-15% -$16.9K ﹤0.01% 2046
2021
Q4
$142K Buy
36,599
+5,122
+16% +$19.9K ﹤0.01% 2139
2021
Q3
$135K Sell
31,477
-6,103
-16% -$20.3K ﹤0.01% 1864
2021
Q2
$114K Buy
37,580
+25,830
+220% +$80K ﹤0.01% 2277
2021
Q1
$39K Sell
11,750
-1,354
-10% -$5.22K ﹤0.01% 2238
2020
Q4
$47K Buy
+13,104
New +$45.9K ﹤0.01% 2048
2019
Q4
Sell
-15,394
Closed -$23K 1788
2019
Q3
$23K Sell
15,394
-4,948
-24% -$8.53K ﹤0.01% 1640
2019
Q2
$42K Sell
20,342
-2,340
-10% -$5.99K ﹤0.01% 1580
2019
Q1
$81K Buy
22,682
+161
+0.7% +$618 ﹤0.01% 1587
2018
Q4
$86K Sell
22,521
-4,390
-16% -$21.6K ﹤0.01% 1489
2018
Q3
$254K Sell
26,911
-924
-3% -$9.18K ﹤0.01% 1454
2018
Q2
$203K Buy
27,835
+2,382
+9% +$14.2K ﹤0.01% 1600
2018
Q1
$127K Sell
25,453
-4,207
-14% -$22.3K ﹤0.01% 1615
2017
Q4
$150K Buy
+29,660
New +$174K ﹤0.01% 1689

Other funds holding ABUS